Figure 2.

PK simulation of meloxicam in the mouse based on mean plasma concentrations from 1.6 mg/kg SC injections. (a) Once‐daily doses bracketing the effective doses (ED 50 and ID 50) from published efficacy studies. (b) Twice‐daily doses predicted to cover whole blood COX‐2 IC 50 and IC 80. (c) Once‐daily doses with 24 h COX‐2 coverage that would result from a theoretical delayed release formulation (T max = 4.5 h). IC 50 and IC 80 values were taken from Warner et al. (1999).